Zenas Biopharma (NASDAQ:ZBIO) Receives “Buy” Rating from HC Wainwright

Zenas Biopharma (NASDAQ:ZBIO – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 186.53% from the company’s current price. A number of […]

Leave a Reply

Your email address will not be published.

Previous post National CineMedia (NASDAQ:NCMI) Stock Rating Lowered by B. Riley
Next post Stunning Highlights From Alpine’s 70th Anniversary At Goodwood You’ll Love